News Releases

Press Releases

  • 3/28/17 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017, at 10:20 a.m. Eastern time. Dr. Aklog will provide a corporate overview, discuss the company’s innovative business model and review PAVmed’s lead products. The conferencemore...
  • 3/28/17 7:15 am EDT

    No Securities Available for Resale Prior to Effectiveness and Nasdaq-related Approvals

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced that the Company has filed a registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”) for the securities underlying the units sold in the Company’s private placement previously announced on February 2, 2017. None of the securities are available for resale until such registration statement is declaredmore...
  • 3/21/17 7:30 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced that it has appointed Dennis M. McGrath as its new Executive Vice President and Chief Financial Officer. Mr. McGrath brings over thirty years of corporate finance and executive experience to PAVmed, spanning both entrepreneurial and public company settings. Since 2000, Mr. McGrath has served in multiple executive leadership roles atmore...
  • 3/9/17 7:00 am EST

    Aggregate Private Placement Proceeds Exceed $2.5 Million

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced the closing of approximately $1.0 million in additional financing, bringing the aggregate gross proceeds of our private placement to $2.5 million. The private placement consists of shares of Series A Convertible Preferred Stock and Series A Warrants. The initial closing was previously announced in February. Dr. Lishan Aklog,more...
  • 2/23/17 7:00 am EST

    Exchange to Provide Incentives for Long-Term Ownership by Existing and New Investors

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) announced today that the Company intends to effectuate a registered exchange offer (the “Exchange”) whereby PAVmed’s Common Stock will become exchangeable for units (the “New Units”). Pursuant to the Exchange, each New Unit will be comprised of one share of Common Stock, identical to the currently outstanding Common Stock, and one newly-issued warrant (the “New Unit Warrant”). Each holder ofmore...
  • 2/17/17 8:00 am EST

    Fourth Quarter 2016 Financial Results Announced

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM,PAVMW), a highly differentiated, multi-product medical device company, today announced financial results for the fourth quarter and year ended December 31, 2016, and that the Company will host a business update conference call on February 22, 2017 at 4:30 p.m. Eastern time. During this call, PAVmed’s Chairman and Chief Executive Officer, Lishan Aklog, M.D., will provide a business update including an overviewmore...
  • 2/3/17 4:31 pm EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM,PAVMW), a highly differentiated, multi-product medical device company, announced that at 4:00 pm today the Securities and Exchange Commission (“SEC”) declared effective the company’s registration statement (the “Registration Statement”) relating to shares of common stock underlying the warrants included in the units issued in the company’s IPO and certain other warrants (the “Warrants”). Accordingly, the Warrants aremore...
  • 2/2/17 7:00 am EST

    Company Considering Exchange Offers to Enhance Value of Outstanding Securities

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced the closing of a $1.5 million financing. The private placement consists of shares of Series A Convertible Preferred Stock (the “Preferred Stock”) and Series A Warrants (the “Series A Warrants”). Dr. Lishan Aklog, Chairman and CEO of PAVmed, stated, “The strong investor interest in our company has been extremely gratifyingmore...
  • 12/19/16 7:00 am EST

    First product regulatory submission marks major corporate milestone

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM,PAVMW), a highly differentiated, multi-product medical device company, today announced that it has filed a 510(k) premarket notification submission with the U.S. Food and Drug Administration (FDA) for its first product, the PortIO™ Intraosseous Infusion System. Lishan Aklog, M.D., Chairman and CEO of PAVmed, said “We are excited to have achieved this important corporate milestone, the submission of ourmore...
  • 12/2/16 7:00 am EST

    - Third Quarter 2016 Financial Results Announced -

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM,PAVMW), a highly differentiated, multi-product medical device company, today announced financial results for the third quarter ended September 30, 2016 and that the Company will host a conference call on December 7, 2016 at 4:30 p.m. Eastern time. During this call, PAVmed’s Chairman and Chief Executive Officer Lishan Aklog, M.D. will provide a business update including an overview of the Company’s near-termmore...

SEC Filings

Click Here to view PAVMed's SEC filings

INVESTOR PRESENTATION

Click Here to view PAVmed’s current Investor Presentation